Global Tumor Ablation Market Size Study & Forecast, by Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, Other Technologies), by Mode of Treatment (Percutaneous Ablation, Laparoscopic Ablation, Surgical Ablation), by Application (Live

Global Tumor Ablation Market Size Study & Forecast, by Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, Other Technologies), by Mode of Treatment (Percutaneous Ablation, Laparoscopic Ablation, Surgical Ablation), by Application (Liver Cancer, Lung Cancer, Kidney Cancer, Bone Metastasis, Others), and Regional Analysis, 2023-2030

Global Tumor Ablation Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% during the forecast period 2023-2030. Tumor ablation is a medical procedure designed to eliminate abnormal tissue, particularly cancerous tumors, within the body. Techniques such as radiofrequency ablation, microwave ablation, cryoablation, and other focused ultrasound are employed to destroy cancer cells. The procedure is guided by imaging methods such as ultrasound or CT scans, which precisely target the tumor while minimizing damage to surrounding healthy tissue. Tumor ablation offers an alternative to traditional surgery for certain patients. The escalating geriatric population, surge in the population base for cancer patients, and growing healthcare expenditure, coupled with the increasing number of hospitals, surgical, and ablation centers are the key factors that are fueling the demand for tumor ablation across the globe. The global prevalence of cancer continues to impact numerous individuals worldwide. For instance, in Australia, Cancer Australia Statistics 2022 reported 162,163 new cases of cancer in 2022, with 88,982 males and 73,181 females affected. Similarly, McMillan Cancer Support's October 2022 update revealed that 3 million individuals were living with cancer in the UK, projected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. This surge in cancer prevalence underscores the increasing demand for surgeries and effective ablation procedures, thereby propelling the market growth at a substantial rate.

In addition, the rising inclination towards minimally invasive surgeries is also exhibiting a positive influence on the growth of the Tumor Ablation Market. These procedures offer less trauma, faster recovery, and lower risks compared to traditional surgeries, attracting both patients and healthcare providers. As reported by Statista, the global minimally invasive surgery segment reached approximately USD 20.5 billion in 2019 and is anticipated to expand to about USD 44.04 billion by 2030. Tumor ablation is a promising alternative for addressing diverse solid tumors, leading to reduced healthcare expenditures and broader treatment possibilities due to technological progress and proven effectiveness. Consequently, these factors are driving the growth of the Tumor Ablation Market. during the estimated period of 2023-2030. Moreover, the growing awareness about ablation procedures over conventional therapeutic and surgical procedures, as well as increasing technological advancements in ablation devices present various lucrative opportunities over the forecast years. However, the stringent regulations & approvals, along with the availability of alternative treatment options are hampering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Tumor Ablation Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising governmental support for high-quality healthcare, rising purchasing power parity, accessible reimbursements, and an increasing incidence of cancer. For instance, in the United States, the Patient Protection and Affordable Care Act (PPACA) advocates for enhanced healthcare quality and affordability through health coverage policies, aiming to reduce healthcare costs for both individuals and the government. Furthermore, initiatives such as the precision medicine initiative contribute to the development of personalized strategies based on the distinctive characteristics of diseases. Consequently, these governmental efforts are expected to enhance the overall healthcare system, fostering market growth. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The surge in the number of patients and the rise in the prevalence of leading healthcare institutions in emerging economies such as India and China present opportunities for market growth. Furthermore, the region is witnessing improvements in healthcare accessibility with favorable government initiatives. For instance, the Indian government provides financial assistance to underprivileged cancer patients through the Health Minister Cancer Patient Fund (HMCPF) scheme. This initiative is anticipated to drive the demand for tumor ablation devices, thereby nurturing the growth of the region.

Major market players included in this report are:
Angiodynamics, Inc. (U.S.)
Boston Scientific Corporation (U.S.)
Galil Medical, Inc. (U.S.)
EDAP TMS S.A. (France)
Healthtronics, Inc. (U.S.)
Medtronic, Plc (U.S.)
Mermaid Medical, Inc. (Denmark)
Mesonix, Inc. (U.S.)
Neuwave Medical, Inc. (U.S.)
Sonacare Medical, LLC (U.S.)

Recent Developments in the Market:
 In April 2023, Johnson & Johnson Service Inc. unveiled the first patient in North America who had been treated as part of its clinical Investigational Device Exemption (IDE) trial. The trial aims to assess the safety and effectiveness of transbronchial microwave ablation utilizing the NEUWAVE FLEX microwave ablation system, guided by the MONARCH platform.
 In April 2023, Compal Electronics, a Taiwanese electronics firm, launched an innovative radiofrequency ablation (RFA) system specifically engineered for percutaneous and intraoperative coagulation and ablation of soft tissue. This system empowers the partial or complete ablation of non-resectable liver lesions. Furthermore, Compal Electronics revealed a bilevel ventilator custom-built for the management of chronic obstructive pulmonary disease (COPD) and respiratory insufficiency stemming from central and/or mixed apneas.

Global Tumor Ablation Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Technology, Mode of Treatment, Application, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Technology:
Radiofrequency (RF) Ablation
Microwave Ablation
Cryoablation
Other Technologies

By Mode of Treatment:
Percutaneous Ablation
Laparoscopic Ablation
Surgical Ablation

By Application:
Liver Cancer
Lung Cancer
Kidney Cancer
Bone Metastasis
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.